BBS-Bioactive Bone Substitutes Oyj (BONEH) - Net Assets
Based on the latest financial reports, BBS-Bioactive Bone Substitutes Oyj (BONEH) has net assets worth €3.79 Million EUR (≈ $4.43 Million USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.37 Million ≈ $10.96 Million USD) and total liabilities (€5.58 Million ≈ $6.52 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of BBS-Bioactive Bone Substitutes Oyj to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.79 Million |
| % of Total Assets | 40.46% |
| Annual Growth Rate | 1.44% |
| 5-Year Change | 65.9% |
| 10-Year Change | N/A |
| Growth Volatility | 107.47 |
BBS-Bioactive Bone Substitutes Oyj - Net Assets Trend (2014–2023)
This chart illustrates how BBS-Bioactive Bone Substitutes Oyj's net assets have evolved over time, based on quarterly financial data. Also explore BONEH total assets for the complete picture of this company's asset base.
Annual Net Assets for BBS-Bioactive Bone Substitutes Oyj (2014–2023)
The table below shows the annual net assets of BBS-Bioactive Bone Substitutes Oyj from 2014 to 2023. For live valuation and market cap data, see BBS-Bioactive Bone Substitutes Oyj (BONEH) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €5.11 Million ≈ $5.97 Million |
+19.60% |
| 2022-12-31 | €4.27 Million ≈ $4.99 Million |
+17.54% |
| 2021-12-31 | €3.63 Million ≈ $4.25 Million |
-40.30% |
| 2020-12-31 | €6.09 Million ≈ $7.12 Million |
+97.69% |
| 2019-12-31 | €3.08 Million ≈ $3.60 Million |
-30.28% |
| 2018-12-31 | €4.42 Million ≈ $5.16 Million |
+308.58% |
| 2017-12-31 | €1.08 Million ≈ $1.26 Million |
-76.48% |
| 2016-12-31 | €4.60 Million ≈ $5.37 Million |
+2.96% |
| 2015-12-31 | €4.46 Million ≈ $5.22 Million |
-0.59% |
| 2014-12-31 | €4.49 Million ≈ $5.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BBS-Bioactive Bone Substitutes Oyj's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1961342400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €80.00K | 1.57% |
| Other Comprehensive Income | €25.75 Million | 503.99% |
| Other Components | €1.40 Million | 27.32% |
| Total Equity | €5.11 Million | 100.00% |
BBS-Bioactive Bone Substitutes Oyj Competitors by Market Cap
The table below lists competitors of BBS-Bioactive Bone Substitutes Oyj ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fsport AB
ST:FSPORT
|
$1.51 Million |
|
BioRestorative Therapies Inc
NASDAQ:BRTX
|
$1.51 Million |
|
Montanaro UK Smaller Companies Investment Trust PLC
LSE:MTU
|
$1.51 Million |
|
Yida China Holdings Ltd
STU:YC2
|
$1.51 Million |
|
WILDCAT PRETR.LS -000028
F:8Y6
|
$1.50 Million |
|
Eurotex Industries and Exports Limited
NSE:EUROTEXIND
|
$1.50 Million |
|
Scheerders van Kerchove's Verenigde fabrieken nv
BR:SCHD
|
$1.50 Million |
|
Eagle Eye Solutions Group plc
LSE:EYE
|
$1.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BBS-Bioactive Bone Substitutes Oyj's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 4,271,343 to 5,108,366, a change of 837,023 (19.6%).
- Net loss of 3,484,000 reduced equity.
- New share issuances of 3,830,000 increased equity.
- Other comprehensive income increased equity by 4,320,639.
- Other factors decreased equity by 3,829,616.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.48 Million | -68.2% |
| Share Issuances | €3.83 Million | +74.98% |
| Other Comprehensive Income | €4.32 Million | +84.58% |
| Other Changes | €-3.83 Million | -74.97% |
| Total Change | €- | 19.60% |
Book Value vs Market Value Analysis
This analysis compares BBS-Bioactive Bone Substitutes Oyj's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | €0.65 | €0.05 | x |
| 2015-12-31 | €0.65 | €0.05 | x |
| 2016-12-31 | €0.67 | €0.05 | x |
| 2017-12-31 | €0.23 | €0.05 | x |
| 2018-12-31 | €0.73 | €0.05 | x |
| 2019-12-31 | €0.49 | €0.05 | x |
| 2020-12-31 | €0.81 | €0.05 | x |
| 2021-12-31 | €0.46 | €0.05 | x |
| 2022-12-31 | €0.52 | €0.05 | x |
| 2023-12-31 | €0.42 | €0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BBS-Bioactive Bone Substitutes Oyj utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.08x
- Recent ROE (-68.20%) is above the historical average (-75.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -6.97% | 0.00% | 0.00x | 2.62x | €-762.06K |
| 2015 | -14.02% | 0.00% | 0.00x | 2.79x | €-1.07 Million |
| 2016 | -14.75% | 0.00% | 0.00x | 2.79x | €-1.14 Million |
| 2017 | -409.53% | 0.00% | 0.00x | 8.96x | €-4.54 Million |
| 2018 | 8.60% | 0.00% | 0.00x | 2.53x | €-61.84K |
| 2019 | -53.20% | -1549.84% | 0.01x | 3.19x | €-1.95 Million |
| 2020 | -44.86% | 0.00% | 0.00x | 2.09x | €-3.34 Million |
| 2021 | -76.25% | 0.00% | 0.00x | 2.89x | €-3.13 Million |
| 2022 | -72.41% | 0.00% | 0.00x | 2.50x | €-3.52 Million |
| 2023 | -68.20% | 0.00% | 0.00x | 2.08x | €-3.99 Million |
Industry Comparison
This section compares BBS-Bioactive Bone Substitutes Oyj's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $37,905,576
- Average return on equity (ROE) among peers: 14.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BBS-Bioactive Bone Substitutes Oyj (BONEH) | €3.79 Million | -6.97% | 1.47x | $1.50 Million |
| Biohit Oyj B (BIOBV) | $98.02 Million | 0.00% | 0.49x | $32.86 Million |
| Nexstim Oyj (NXTMH) | $-294.27K | 0.00% | 0.00x | $75.48 Million |
| Revenio Group Corporation (REG1V) | $15.99 Million | 42.84% | 0.19x | $437.29 Million |
About BBS-Bioactive Bone Substitutes Oyj
BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, manufactures, and commercializes bioactive medical devices and implants for orthopedic surgery in Finland. It offers ARTEBONE, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins used primarily for the treatment of bone defects and healing problems in extremities, such as foot… Read more